» Articles » PMID: 35195232

Treatment-related Fluctuations in Guillain-Barré Syndrome​: Clinical Features and Predictors of Recurrence

Overview
Publisher Thieme
Specialties Neurology
Psychiatry
Date 2022 Feb 23
PMID 35195232
Authors
Affiliations
Soon will be listed here.
Abstract

Background: A treatment-related fluctuation (TRF) in a patient with Guillain-Barré syndrome (GBS) is defined as clinical deterioration within two months of symptom onset following previous stabilization or improvements with treatment.

Objective: To investigate the clinical characteristics and factors that could increase the risk of relapse of GBS in patients with and without TRFs.

Methods: Retrospective review of medical records of patients (>18 years) with GBS evaluated between January/2006 and July/2019. Demographic and clinical characteristics, ancillary studies, treatment received, and the clinical course of patients with and without TRFs were analyzed.

Results: Overall, 124 cases of GBS were included; seven (5.6%) presented TRFs. GBS-TRF cases were triggered more frequently by infectious mononucleosis (28.57 vs. 8.55%; p=0.01). GBS-TRF were initially treated with plasmapheresis more frequently than those without TRF (14.29 vs. 1.70%; p=0.0349). Combined treatment (71.43 vs. 4.27%; p<0.001) and corticosteroids (42.86 vs. 1.71%; p<0.001) were more commonly used in the GBS-TRF group. GBS-TRF patients presented a higher median initial disability score (4 vs. 2; p=0.01).

Conclusions: Patients with GBS triggered by infectious mononucleosis and a high degree of initial disability have higher chances of developing TRFs. Although patients with TRF were treated with plasmapheresis more often, the total number was too low to suggest a link between plasma exchange and TRF.

Citing Articles

Treatment-Related Fluctuation in Guillain-Barre Syndrome With the Acute Motor-Sensory Axonal Neuropathy (AMSAN) Variant: A Case Report.

Hernandez E, Dominguez D, Medina-Rioja R, Martinez-Angeles V, Carlos Lopez-Hernandez J Cureus. 2024; 16(7):e65201.

PMID: 39176336 PMC: 11340779. DOI: 10.7759/cureus.65201.


Differentiating recurrent Guillain-Barre syndrome and acute-onset chronic inflammatory polyneuropathy: literature review.

Inan B, Bekircan-Kurt C, Demirci M, Erdem-Ozdamar S, Tan E Acta Neurol Belg. 2024; 124(5):1467-1475.

PMID: 38664341 DOI: 10.1007/s13760-024-02557-2.

References
1.
Hadden R, Karch H, Hartung H, Zielasek J, Weissbrich B, Schubert J . Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology. 2001; 56(6):758-65. DOI: 10.1212/wnl.56.6.758. View

2.
. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Lancet. 1997; 349(9047):225-30. View

3.
Ruts L, Drenthen J, Jacobs B, van Doorn P . Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology. 2010; 74(21):1680-6. DOI: 10.1212/WNL.0b013e3181e07d14. View

4.
van der Meche F, Schmitz P . A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med. 1992; 326(17):1123-9. DOI: 10.1056/NEJM199204233261705. View

5.
Ruts L, van Koningsveld R, van Doorn P . Distinguishing acute-onset CIDP from Guillain-Barré syndrome with treatment related fluctuations. Neurology. 2005; 65(1):138-40. DOI: 10.1212/01.wnl.0000167549.09664.b8. View